Get the Stockscreener App
74.49
6.35%
-5.05
Praxis Precision Medicines Inc stock is traded at $74.49, with a volume of 491.25K.
It is down -6.35% in the last 24 hours and down -4.82% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
See More
Previous Close:
$79.54
Open:
$80.56
24h Volume:
491.25K
Relative Volume:
1.40
Market Cap:
$1.39B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-8.1232
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
-17.94%
1M Performance:
-4.82%
6M Performance:
+39.39%
1Y Performance:
+84.02%
1-Day Range:
$74.30
$80.96
1-Week Range:
$74.30
$91.60
52-Week Range:
$33.01
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
74.49 | 1.39B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Long Term Trading Analysis for (PRAX) - Stock Traders Daily
CIBC Asset Management Inc Purchases 117,817 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Trading Up 4.9%Here's Why - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Sees Significant Growth in Short Interest - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 8.6%Should You Sell? - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year HighWhat's Next? - MarketBeat
Jefferies maintains Praxis stock with $305 target, bullish on catalysts - MSN
Mirae Asset Global Investments Co. Ltd. Takes $48,000 Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 6.5%Here's What Happened - MarketBeat
Deutsche Bank Aktiengesellschaft Begins Coverage on Praxis Precision Medicines (NASDAQ:PRAX) - MarketBeat
PRAX stock soars to 52-week high, hits $90.33 amid robust gains - MSN
PRAX stock soars to 52-week high, hits $90.33 amid robust gains By Investing.com - Investing.com South Africa
Praxis Precision Medicines (NASDAQ:PRAX) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Deutsche Bank sets $111 target for Praxis Precision shares By Investing.com - Investing.com Nigeria
Deutsche Bank Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy Recommendation - Nasdaq
The Analyst Verdict: Praxis Precision Medicine In The Eyes Of 4 Experts - Benzinga
What the Options Market Tells Us About Praxis Precision Medicine - Benzinga
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 6.5% – Time to Sell? - Defense World
Deutsche Bank sets $111 target for Praxis Precision shares - MSN
Deutsche Bank Initiates Coverage on Praxis Precision Medicines With Buy Rating, $111 Price Target - Marketscreener.com
Praxis Precision Medicines’ (PRAX) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 1-Year HighHere's Why - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 5.8%What's Next? - MarketBeat
China Universal Asset Management Co. Ltd. Makes New Investment in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Morgan Stanley's Strategic Acquisition of Praxis Precision Medic - GuruFocus.com
Should You Invest in Nasdaq Inc (NDAQ) Now? - The News Heater
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Praxis Awards Strategic Compensation Package: $80.26 Options Grant Signals Talent Acquisition Push - StockTitan
Praxis Precision Medicines to Present at Two February Investor Conferences - The Manila Times
CNS Drug Developer Praxis Lines Up Exclusive Investor Access at Guggenheim & Oppenheimer Events - StockTitan
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives $149.11 Average Price Target from Brokerages - MarketBeat
Learn to Evaluate (PRAX) using the Charts - Stock Traders Daily
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by JPMorgan Chase & Co. - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Praxis Precision Medicines (PRAX) Stock Price, News & Analysis - MarketBeat
Noteworthy Wednesday Option Activity: PRAX, ORCL, SOC - Nasdaq
Jefferies maintains Praxis stock with $305 target, bullish on catalysts By Investing.com - Investing.com South Africa
Truist Financial Issues Positive Forecast for Praxis Precision Medicines (NASDAQ:PRAX) Stock Price - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Shares Up 8.5% Following Analyst Upgrade - Defense World
Expert Outlook: Praxis Precision Medicine Through The Eyes Of 5 Analysts - Benzinga
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Praxis Precision Medicines Inc Stock (PRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Sale |
80.20 |
8,239 |
660,827 |
10,301 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Option Exercise |
56.94 |
4,374 |
249,056 |
10,801 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Sale |
81.78 |
5,188 |
424,318 |
5,613 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):